Celldex Therapeutics Stock
Celldex Therapeutics Stock
Heavy losses for Celldex Therapeutics today as the stock fell by -€1.000 (-4.390%).
Currently there is a rather positive sentiment for Celldex Therapeutics with 9 Buy predictions and 3 Sell predictions.
As a result the target price of 39 € shows a very positive potential of 78.9% compared to the current price of 21.8 € for Celldex Therapeutics.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Celldex Therapeutics stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Celldex Therapeutics in the next few years
Pros
?
B****
?
G***** c******* t* c**********
?
M***** P*******
Cons
?
S********** s********
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Celldex Therapeutics vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Celldex Therapeutics | -4.390% | -0.909% | -13.492% | -13.492% | -0.909% | -45.798% | 51.389% |
| Vaxart Inc. | -0.740% | -3.571% | -4.187% | -70.346% | -3.571% | -70.748% | -95.135% |
| Larimar Therapeutics Inc. | -2.080% | -15.060% | -9.615% | -24.599% | -15.060% | -24.599% | -83.566% |
| aTyr Pharma Inc | -2.730% | -10.833% | -12.295% | -86.140% | -10.833% | -76.719% | -81.678% |
Comments
Celldex Therapeutics (NASDAQ:CLDX) had its price target raised by analysts at Barclays PLC from $21.00 to $24.00. They now have an "underweight" rating on the stock.
Show more
Ratings data for CLDX provided by MarketBeat
Celldex Therapeutics (NASDAQ:CLDX) had its price target lowered by analysts at Barclays PLC from $25.00 to $21.00. They now have an "underweight" rating on the stock.
Show more
Ratings data for CLDX provided by MarketBeat
Celldex Therapeutics (NASDAQ:CLDX) is now covered by analysts at Barclays PLC. They set an "underweight" rating and a $25.00 price target on the stock.
Show more
Ratings data for CLDX provided by MarketBeat